Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial

Authors

Institutions

Publication Details

Journal
Journal of Hematology & Oncology
Published
2025-11-26
DOI
https://doi.org/10.1186/s13045-025-01770-7
Primary Topic
Neuroblastoma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial

Ellen M. Basu, Audrey Mauguen, Stephen S. Roberts, Nai‐Kong V. Cheung et al.
Journal of Hematology & Oncology
Neuroblastoma Research and Treatments
article

Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial

Ellen M. Basu, Audrey Mauguen, Stephen S. Roberts, Nai‐Kong V. Cheung, Brian H. Kushner, Shakeel I. Modak
article en

Abstract

No abstract available for this paper.
Journal of Hematology & OncologyVol. 18(1)
Memorial Sloan Kettering Cancer Center (US), Oregon Health & Science University (US)
Openalex Percentile: Top 49%
Neuroblastoma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.